|
|
Post by dpca10 on Nov 23, 2015 15:41:24 GMT -5
There is also the possibility that he resigned because he knew he was not the right person for the job. My guess is Sanofi is 6 months behind on their rollout plan and need to be pressured and held accountable for their end of the agreement. If this is the case there needs to be a plan to make up ground not just continue at the current pace, considering mannkinds financial situation. Edstrom might not be the man for that task. Furthermore the board under Mann might have been heavily directing traffic, if that was the case he was a paper CEO in any case and probably should step aside for more direct control by the decision makers.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 23, 2015 17:07:20 GMT -5
The postulate of Matt resigning is pure fear mongering. I see Matt as Al's confidant, no way Al could be upset with Matt.
|
|
|
|
Post by EveningOfTheDay on Nov 23, 2015 18:07:18 GMT -5
Well, shorts have the company exactly where they have wanted it for quite a while, apparently out of options. To tell the truth, the more I learned about MNKD the more I felt there was a power play between Mann and other interests set on controlling the corporation or at least a big part of it. Mann is fairly mighty and he might have thought he had a chance to win in this game, but I can now, with some certainty level, can say that it appears the opposite side has the upper hand and therefore the interests behind it must be extremely well financed and connected. A part of me thinks that the best that could happen for long term investors is that Mann gives in to pressure and accommodates the interest of those involved in the game. I have a feeling that the sp would quickly jump considerably if this happened. Unfortunately or fortunately, depending on how you perceive the issue, I do not think Mann will give in, but then again he is in his 90s. His enemies have proven that they are willing to patiently wait for a long time.
|
|
|
|
Post by thekindaguyiyam on Nov 23, 2015 18:14:39 GMT -5
Friday everyone happy the resignation of Hakan, now all negative for Al CEO ... I do not understand. How to get out of this mess? the beauty of owning a stock you are uncomfortable with is that you can always sell and that control belongs to you. It's all in one's confidence based on their own dd; no-one can give that to you, or take it away. |
|
|
|
Post by jurystillout on Nov 23, 2015 18:16:32 GMT -5
There seems to be a general feeling of gloom on this board, I don't really share this feeling. I'm not happy about the position mnkd finds itself in however I honestly do feel better about mnkds future today than I did last week at this time. Nothing has really changed other than the ceo has resigned/fired whatever. I truly believe this change is a very positive change, I don't wish any ill will,or dislike Hakan as as person however as a CEO I really think he is responsible for the position we find mnkd in today. I agree with Katanes that Matt will be around as long as he wants however I hope Al isn't considering him for a promotion, in my opinion it would be a lateral move and not what we need.
|
|
|
|
Post by bill on Nov 23, 2015 19:18:50 GMT -5
Help me out here folks...
It seems to me that MNKD's only got two chances to survive their current predicament; a TS license with substantial up-front funding or an aggressive move by the SEC to stop the illegal manipulation of MNKD's stock price. I know we all doubt that the latter is going to happen, so let's cross that off our list.
I doubt MNKD can even sell the business to SNY anymore because SNY can see that MNKD doesn't have the cash to hang around long enough to ever see any Afrezza profits, i.e., MNKD is on a path to bankruptcy within 6 months. Why pay for something that you're pretty sure you'll get for free within the year? SNY can even accelerate Afrezza marketing and adoption at this point because the resulting prescriptions won't catch up with MNKD's debt before bankruptcy. That approach by SNY would eliminate any practical way for MNKD to claim they didn't use reasonable efforts to bring Afrezza to the marketplace.
Give the previous situation there's no reason for SNY (or anyone else) to buy-in to MNKD; doesn't help SNY and only weakens the chance that MNKD will go bankrupt.
MNKD's also unlikely to succeed in a public stock offering, even if you ignore that such an offering would increase the shares available for the shorts. The shorts would simply drive the stock price down again and eliminate MNKD's ability to raise a substantial amount of cash.
I keep coming to the inevitable conclusion that's it's a TS license deal or bust. If that's true then we need to figure how likely that would be, how much cash it would raise, and when the licensing deal would conclude.
Thoughts?
|
|
|
|
Post by wildpig on Nov 23, 2015 19:24:24 GMT -5
no such luck
|
|
|
|
Post by ricguy on Nov 23, 2015 19:27:19 GMT -5
u the same wildpig that bashes MNKD on StockTwits? |
|
|
|
Post by benyiju on Nov 23, 2015 21:12:24 GMT -5
The postulate of Matt resigning is pure fear mongering. I see Matt as Al's confidant, no way Al could be upset with Matt. Kastanes, we really don't know that about Al and Matt. Especially now that we've seen what Al could do to Hakan, someone he clearly had a lot of confidence in until recently. Unless Hakan did something really bad, the Company's announcement of his 'retirement' was shockingly ungrateful and very bad business etiquette. And, frankly, after Matt's bungling of several critical debt and cash moves the past few months, he might deserve to be sacked more than Hakan. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 23, 2015 21:19:52 GMT -5
Completely disagree, every conference call I listened to, it was Matt that stepped up to address questions normally answered by the CEO. Matt takes orders from the CEO, so IF MannKind performed poorly financially, blame lies with Hakan.
|
|
|
|
Post by benyiju on Nov 23, 2015 21:26:34 GMT -5
Completely disagree, every conference call I listened to, it was Matt that stepped up to address questions normally answered by the CEO. Matt takes orders from the CEO, so if MannKind performed poorly financially, blame lies with Hakan. Fair enough, the buck stops with the CEO, but in terms of who is actually managing these operations, it's the CFO's responsibility to manage debit and cash issues. Unless you think Matt wanted to do things differently and it was Hakan who forced him into errors of August debt and TASE offering fiascos. |
|
|
|
Post by nylefty on Nov 23, 2015 21:37:41 GMT -5
When I started buying this stock last Spring I put a lot of weight on what seemed to be the conventional wisdom that many (if not most) doctors wait for a year after a drug is launched before they start prescribing it. There was a lot of discussion about this at the time and I have to wonder why there's no mention of it in all the doom and gloom posts on this board these days.
Last Spring I was telling people that I expected Afrezza sales to take off sometime in the first quarter of 2016. Why has this possibility been written off by so many here?
|
|
|
|
Post by benyiju on Nov 23, 2015 21:43:00 GMT -5
When I started buying this stock last Spring I put a lot of weight on what seemed to be the conventional wisdom that many (if not most) doctors wait for a year after a drug is launched before they start prescribing it. There was a lot of discussion about this at the time and I have to wonder why there's no mention of it in all the doom and gloom posts on this board these days. Last Spring I was telling people that I expected Afrezza sales to take off sometime in the first quarter of 2016. Why has this possibility been written off by so many here? I don't think it has been written off, but I think the current financial situation makes it feel like it could be too little too late. That and the fact that many of us were expecting more traction 2H2015 (and that was clearly MNKD and maybe SNY's thinking, too, based on Hakan's slip in the 2Q2015 CC). The fact that scripts have been stagnant for 6 months has shaken the faith of many. Personally, I can't imagine they won't 'take off' in next 6-12 months, but I admit that I am concerned about the 'too little, too late' argument now, much more than I was 2-3 months ago. |
|
|
|
Post by benyiju on Nov 23, 2015 21:52:31 GMT -5
However, that being said, I am still thinking very seriously about adding this week or next if/when current malaise and tax loss selling drives SP down sub-$2. I still believe! Amen!
|
|
|
|
Post by dreamboatcruise on Nov 23, 2015 21:55:46 GMT -5
When I started buying this stock last Spring I put a lot of weight on what seemed to be the conventional wisdom that many (if not most) doctors wait for a year after a drug is launched before they start prescribing it. There was a lot of discussion about this at the time and I have to wonder why there's no mention of it in all the doom and gloom posts on this board these days. Last Spring I was telling people that I expected Afrezza sales to take off sometime in the first quarter of 2016. Why has this possibility been written off by so many here? I believe that improvement in formulary would have to come first. Given that initial 2016 formularies are already out now that it is open enrollment and we haven't heard of Afrezza being added to many/any, I would say that chance of Q1 surge is seeming less likely. Hopefully some improvement, but I would be surprised (oh so happily surprised) if the scrip counts really took off. Without a great deal of effort we are stuck looking at formulary coverage from free sources like formularylookup.com. I believe they reflect what is in effect at the current moment. It is possible that Afrezza has been added to some 2016 formularies, but I would think that would be being traded on by those with better access to data if that were the case and our share price would be higher. I'm sure for people paying for the data the 2016 info is readily available. |
|
